MicroRNA-146a-5p enhances ginsenoside Rh2-induced anti-proliferation and the apoptosis of the human liver cancer cell line HepG2

被引:35
作者
Chen, Weiwen [1 ,2 ]
Chu, Shuai [1 ]
Li, Haixia [1 ]
Qiu, Yurong [1 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Med Labs, 1838 North Guangzhou Ave, Guangzhou 510515, Guangdong, Peoples R China
[2] Guangzhou Twelfth Peoples Hosp, Med Labs, Guangzhou 510620, Guangdong, Peoples R China
关键词
ginsenoside Rh2; liver cancer; antitumor; promotion; microRNA-146a-5p; HEPATOCELLULAR-CARCINOMA; RH2; PROLIFERATION; GROWTH; NRF2;
D O I
10.3892/ol.2018.9235
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Liver cancer is one of the leading causes of malignancy-associated mortality worldwide and its clinical therapy remains very challenging. Ginsenoside Rh2 (Rh2) has been reported to have antitumor effects on some types of cancer, including liver cancer. However, its regulatory mechanism has not been extensively evaluated. In the present study, Rh2 increased the expression of microRNA (miR)-200b-5p, miR-224-3p and miR-146a-5p, and decreased the expression of miR-26b-3p and miR-29a-5p. Of the three upregulated miRs, miR-146a-5p exhibited the highest fold elevation. In accordance with a previous study, Rh2 effectively inhibited the survival of liver cancer cells in vitro and in a mouse model. In addition, it was observed that Rh2 markedly promoted liver cancer apoptosis and inhibited colony formation. Cell apoptosis and the inhibition of cell survival as well as colony formation induced by Rh2 were enhanced and weakened by miR-146a-5p overexpression and inhibition, respectively. The results of the present study provide further evidence of the antitumor effect of Rh2 in liver cancer and also demonstrate that this effect may be mediated via the regulation of miR-146a-5p expression in the liver cancer cell line HepG2. The results indicated that miR-146a-5p may be a promising regulatory factor in Rh2-mediated effects in liver cancer.
引用
收藏
页码:5367 / 5374
页数:8
相关论文
共 24 条
  • [1] MicroRNA functions in animal development and human disease
    Alvarez-Garcia, I
    Miska, EA
    [J]. DEVELOPMENT, 2005, 132 (21): : 4653 - 4662
  • [2] Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells
    An, In-Sook
    An, Sungkwan
    Kwon, Ku Jung
    Kim, Young Joo
    Bae, Seunghee
    [J]. ONCOLOGY REPORTS, 2013, 29 (02) : 523 - 528
  • [3] [Anonymous], TUMOUR BIOL
  • [4] Ginsenoside Rh2 inhibits metastasis of glioblastoma multiforme through Akt-regulated MMP13
    Guan, Ning
    Huo, Xiaochuan
    Zhang, Zhenxing
    Zhang, Shoudan
    Luo, Junsheng
    Guo, Wenshi
    [J]. TUMOR BIOLOGY, 2015, 36 (09) : 6789 - 6795
  • [5] Collapsin response mediator protein 4 isoforms (CRMP4a and CRMP4b) have opposite effects on cell proliferation, migration, and invasion in gastric cancer
    Guo, Haijian
    Xia, Bing
    [J]. BMC CANCER, 2016, 16
  • [6] Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through targeting IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells
    Han, Songhee
    Jeong, Ae Jin
    Yang, Heejung
    Bin Kang, Kyo
    Lee, Haeri
    Yi, Eun Hee
    Kim, Byung-Hak
    Cho, Chung-Hyun
    Chung, Jin Woong
    Sung, Sang Hyun
    Ye, Sang-Kyu
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 2016, 194 : 83 - 90
  • [7] Ginsenoside Rh2 inhibits proliferation and induces apoptosis in human leukemia cells via TNF-α signaling pathway
    Huang, Jingjia
    Peng, Kunjian
    Wang, Linghao
    Wen, Bin
    Zhou, Lin
    Luo, Tiao
    Su, Min
    Li, Jijia
    Luo, Zhiyong
    [J]. ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2016, 48 (08) : 750 - 755
  • [8] Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.21492, 10.3322/caac.20115, 10.3322/caac.20107]
  • [9] Joshi Pooja, 2014, World J Methodol, V4, P59, DOI 10.5662/wjm.v4.i2.59
  • [10] EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2
    Li, Shaoyi
    Gao, Yun
    Ma, Weining
    Guo, Wenchang
    Zhou, Gang
    Cheng, Tianci
    Liu, Yunhui
    [J]. TUMOR BIOLOGY, 2014, 35 (06) : 5593 - 5598